An albumin, collagen IV, and longitudinal diameter of spleen scoring system superior to APRI for assessing liver fibrosis in chronic hepatitis B patients

• Very simple scoring system for assessing liver fibrosis in chronic hepatitis B patients.
• The indexes can be checked even in small hospital.
• Distinguish mild to moderate fibrosis from significant fibrosis very well.
• Superior to APRI.

SummaryObjectivesThe aim of this study was to screen the non-invasive indexes correlated with liver fibrosis and establish a scoring system for the diagnosis of liver fibrosis in hepatitis B patients.MethodsData of 34 non-invasive indexes were collected for 208 hepatitis B patients. Correlation analysis and stepwise discriminant analysis was used to screen out indexes useful for the diagnosis of liver fibrosis. Finally, a scoring system composed of indexes screened out by stepwise discriminant analysis was established for the assessment of liver fibrosis.ResultsTwenty-one indexes correlating with liver fibrosis were screened out by correlation analysis; hyaluronic acid had the highest r-value, 0.456. A scoring system including albumin, collagen IV, and the longitudinal diameter of the spleen was established. The areas under the receiver operating characteristic curves (AUC) for this scoring system and the aspartate aminotransferase to platelet ratio index (APRI) in differentiating S3–4 from S0–2 were 0.79 (95% confidence interval (CI) 0.72–0.85) and 0.27 (95% CI 0.18–0.35), respectively. With a cut-off value of <3, the presence of significant fibrosis (S3–4) could be excluded by this scoring system with a negative predictive value of 86.1% and sensitivity of 86.8%. With a cut-off of >6, the presence of S3–4 fibrosis could be correctly identified with a positive predictive value of 73.6% and specificity of 87.6%. Using this scoring system, 53.4% of patients could be classified correctly and avoid liver biopsy.ConclusionsThe scoring system provides a simpler method to identify significant fibrosis (S3–4) in chronic hepatitis B patients.